Mergers & Acquisitions - Biotechnology, Oncology

Filter

Current filters:

BiotechnologyOncology

Popular Filters

1 to 25 of 50 results

Prima BioMed to acquire Immutep for $28 million

Prima BioMed to acquire Immutep for $28 million

03-10-2014

France-based Immutep, a late-stage private biopharmaceutical company in the rapidly growing field of…

BiotechnologyFranceImmunologicalsImmutepMergers & AcquisitionsOncologyPrima BioMed

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

29-09-2014

Daiichi Sankyo and Ambit Biosciences have entered into a definitive merger agreement under which Daiichi…

Ambit BiosciencesBiotechnologyDaiichi SankyoJapanMergers & AcquisitionsOncologyquizartinib

Soligenix acquires Ph III-ready oncology clinical program

Soligenix acquires Ph III-ready oncology clinical program

05-09-2014

US clinical-stage biopharma firm Soligenix has acquired a novel orphan drug candidate, known as SGX301…

BiotechnologyhypericinMergers & AcquisitionsOncologySGX301Soligenix

Oncothyreon acquires Alpine Biosciences

Oncothyreon acquires Alpine Biosciences

12-08-2014

US biotech firm Oncothyreon says that it has acquired Alpine Biosciences, of Seattle, Washington, a privately…

Alpine BiosciencesBiotechnologyBusiness FinanceImmunotherapyMedicineMergers & AcquisitionsOncologyOncothyreonRare diseasesUSA

Roche to acquire Seragon in deal that could reach over $1.7 billion

Roche to acquire Seragon in deal that could reach over $1.7 billion

02-07-2014

Swiss drug major Roche says its USA-based biotech subsidiary Genentech has entered into a definitive…

BiotechnologyGenentechMergers & AcquisitionsOncologyRocheSeragon Pharmaceuticals

BioAlliance and Topotarget progress merger plan

BioAlliance and Topotarget progress merger plan

01-07-2014

France-base BioAlliance Pharma and Denmark’s Topotarget say that the shareholders of both companies…

BioAlliance PharmaBiotechnologyMergers & AcquisitionsOncologyOnxeoTopotarget

Definitive merger plan between BioAlliance Pharma and Topotarget

Definitive merger plan between BioAlliance Pharma and Topotarget

22-05-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget have confirmed details of…

BioAlliance PharmaBiotechnologyMergers & AcquisitionsOncologyOnxeoTopotarget

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

07-04-2014

Swiss drug major Roche has entered to a worldwide collaboration with Spanish functional genomics firm…

BiotechnologyIQuumLicensingMergers & AcquisitionsOncologyORY-1001Oryzon GenomicsRoche

Tiziana Pharma plans listing via reverse takeover

Tiziana Pharma plans listing via reverse takeover

31-03-2014

Tiziana Pharma, a recently-established UK biotech company that has licensed technology for a potential…

BiotechnologyMergers & AcquisitionsOncologyTiziana

Verastem acquires cancer stem cell inhibitor VS-4718 rights from Poniard

27-02-2014

US drug developer Verastem has acquired the license to VS-4718, which targets cancer stem cells, held…

BiotechnologyMergers & AcquisitionsOncologyPoniard PharmaceuticalsVerastemVS-4718

Novartis to acquire CoStim, expanding cancer immunotherapy research program

Novartis to acquire CoStim, expanding cancer immunotherapy research program

17-02-2014

Swiss drug major Novartis said this morning that it is broadening its cancer immunotherapy research program…

BiotechnologyCoStim PharmaceuticalsMergers & AcquisitionsNovartisOncology

Agenus to acquire Switzerland’s 4-Antibody AG

14-01-2014

US biotech firm Agenus has entered into a definitive agreement to acquire 4-Antibody AG, a private Switzerland-headquartered…

4-Antibody AGAgenusBiotechnologyGITRMergers & AcquisitionsOncologyOX40

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

31-12-2013

China’s Walvax Biotech has revealed it plans to acquire a controlling 64% equity stake in Shanghai’s…

Asia-PacificBiosimilarsBiotechnologyChinaMergers & AcquisitionsOncology

Senesco enters merger accord with Fabrus

31-12-2013

USA-based biotech firm Senesco Technologies has agreed to terms and executed a non-binding Letter of…

BiotechnologyFabrusMergers & AcquisitionsOncologySenesco Technologies

Advaxis rockets on out-licensing ADXS-HPV in Asia

09-12-2013

Shares of US cancer drug developer Advaxis leapt 22% to $4.38 in pre-market trading as the company revealed…

AdvaxisADXS-HPVBiotechnologyGlobal BioPharmaLicensingMergers & AcquisitionsOncologyTaiwan Biotech

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene

04-12-2013

US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

Korea’s SillaJen to acquire Jennerex in up to $150 million deal

27-11-2013

Privately-held South Korean firm SillaJen says it has executed a definitive merger agreement to acquire…

BiotechnologyJennerexMergers & AcquisitionsOncologyPexa-VecSillaJenTransgene

Clovis Oncology buys Italian firm for $200 million

21-11-2013

US biotech firm Clovis Oncology says it has acquired EOS (Ethical Oncology Science), a privately-held…

BiotechnologyClovis OncologylucitanibMergers & AcquisitionsOncologyServier

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

09-10-2013

PharmAkea Therapeutics and Bay City Capital have entered a strategic collaboration with Celgene designed…

BiotechnologyCelgeneMergers & AcquisitionsNorth AmericaOncologyPharmAkeaResearch

Otsuka confirms takeover bid for Astex Pharmaceuticals for $886 million

05-09-2013

Following heavy speculation on Wednesday (see The Pharma Letter story earlier today), this morning Japanese…

Astex PharmaceuticalsBiotechnologyMergers & AcquisitionsOncologyOtsukaPharmaceutical

Otsuka said to be buying Astex Pharma

05-09-2013

Japanese mid-size drugmaker Otsuka (TYO: 4768) is planning to acquire USA-based Astex Pharmaceuticals…

Astex PharmaceuticalsBiotechnologyMergers & AcquisitionsOncologyOtsukaPharmaceutical

Onyx Pharma accepts increased bid from Amgen

27-08-2013

Amgen (Nasdaq: AMGN), the world largest independent biotech group, said on Sunday (August 25) that the…

AmgenBayerBiotechnologyKyprolisMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizer

1 to 25 of 50 results

Back to top